CDKN1B and neoplasm: The enhanced expression of miR-221/222 in glioblastoma can promote S-phase entry by targeting the cell cycle inhibitors (p27 and p57), and knockdown of miR-221/222 strongly reduced tumor growth in vivo (44, 45).